Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group

Pediatric Blood and Cancer

Volumn 52, Issue 7, 2009, Pages 808-813

  Tomizawa, Daisuke ^a   Koh, Katsuyoshi ^b   Hirayama, Masahiro ^c   Miyamura, Takako ^d   Hatanaka, Michiki ^e   Saikawa, Yutaka ^f   Ishii, Eiichi ^g  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c MIE UNIVERSITY   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e FUKUOKA UNIVERSITY   (Japan)

^f KANAZAWA MEDICAL UNIVERSITY   (Japan)

^g EHIME UNIVERSITY   (Japan)

Author keywords

Infant acute lymphoblastic leukemia; MLL gene; Recurrent; Refractory

Indexed keywords

ACLARUBICIN; ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ENOCITABINE; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; PIRARUBICIN; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; ARTICLE; AUTISM; BRONCHIOLITIS OBLITERANS; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; CHILD; CHRONIC DIARRHEA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORNEA OPACITY; DRUG DOSE ESCALATION; DRY EYE; FASCIITIS; FEMALE; FOLLOW UP; GENE; GENE REARRANGEMENT; HUMAN; HYPOPIGMENTATION; HYPOTHYROIDISM; INFANT; INTELLECTUAL IMPAIRMENT; INTERSTITIAL PNEUMONIA; LEARNING DISORDER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MALNUTRITION; MLL GENE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RETINA VASCULITIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCHOOL CHILD; SCLERODERMA; SHORT STATURE; SURVIVAL RATE; SURVIVAL TIME; TOOTH DISEASE; WHOLE BODY RADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM RECURRENCE, LOCAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 67650470938     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21975     Document Type: Article

References (21)

1. Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999;94:1209-1217. (Pubitemid 29380401)
2. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children's Oncology Group. Blood 2006;108:441-451.
3. Silverman LB, McLean TW, Gelber RD, et al. Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer Institute Consortium. Cancer 1997;80:2285-2295. (Pubitemid 28007400)
4. Pieters R, Schrappe M, De Lorenzo P, et al.Atreatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet 2007;370:240-250. (Pubitemid 47082422)
5. Isoyama K, Eguchi M, Hibi S, et al. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: Results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol 2002;118:999-1010. (Pubitemid 35025962)
6. Kosaka Y, Koh K, Kinukawa N, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: Outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004;104:3527-3534. (Pubitemid 39564423)
7. Tomizawa D, Koh K, Sato T, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: A final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007;21:2258-2263. (Pubitemid 350011697)
8. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia 1998;12:1344-1348. (Pubitemid 28442379)
9. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004;18:521-529.
10. Choi S, Henderson MJ, Kwan E, et al. Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood 2007;110:632-639.
11. Klumper E, Pieters R, Veerman AJ, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995;86:3861-3868.
12. Li AH, Rosenquist R, Forestier E, et al. Detailed clonality analysis of relapsing precursor B acute lymphoblastic leukemia: Implications for minimal residual disease detection. Leuk Res 2001; 25:1033-1045. (Pubitemid 33000483)
13. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse-the Children's Cancer Group Experience. Cancer 1998;82:1387-1395. (Pubitemid 28155403)
14. Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis. Blood 2003;101:3835-3839. (Pubitemid 36857854)
15. Chessells JM, Veys P, Kempski H, et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 2003;123:396-405. (Pubitemid 37363478)
16. Einsiedel HG, von Stackelberg A, Hartmann R, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005;23:7942-7950. (Pubitemid 46657394)
17. Henze G, Fengler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991;78:1166-1172.
18. Schroeder H, Garwicz S, Kristinsson J, et al. Outcome after first relapse in children with acute lymphoblastic leukemia: A population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Med Pediatr Oncol 1995;25:372-378.
19. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002;30:41-47. (Pubitemid 34886688)
20. Brown P, Levis M, McIntyre E, et al. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 2006;20:1368-1376. (Pubitemid 44084049)
21. Stam RW, den Boer ML, Schneider P, et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005;106:2484-2490. (Pubitemid 41510823)